Contango Announces Year-end Reserves, Fourth Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
85
Contango Announces Year-end Reserves, Fourth Quarter 2016 Production and First Quarter 2017 Production Guidance

HOUSTON, March 10, 2017 (GLOBE NEWSWIRE) -- Contango Oil & Gas Company (NYSE MKT:MCF) (“Contango”) announced today its year-end reserves and fourth quarter 2016 production results. 

Year-end 2016 Proved Reserves

As of December 31, 2016, our independent third-party engineering firms estimated our proved oil and natural gas reserves to be approximately 151.8 Bcfe compared with 187.2 Bcfe of proved reserves as of December 31, 2015, a decrease that is attributable primarily to, in part: the impact of the decline in commodity prices on the volume and value of our proved reserves; the impact of the significant reduction in our capital spending in 2016; and the sale of non-core conventional assets in Colorado. At the end of 2016, the composition of our proved reserves, volumetrically, was 69% natural gas, 14% oil and condensate and 17% natural gas liquids, compared to 68% natural gas, 15% oil and condensate and 17% natural gas liquids at December 31, 2015.  These estimates were prepared in accordance with reserve reporting guidelines mandated by the Securities and Exchange Commission (“SEC”).  Negative revisions to our proved reserves related to price declines were an estimated 8.3 Bcfe and $49.4 million in PV-10 value.

As of December 31, 2016, the PV-10 value of our proved reserves was approximately $166 million, compared to the PV-10 value of $249 million as of December 31, 2015, a decrease related to lower reserves and to the decline in the average commodity prices used in determining PV-10 in accordance with SEC guidelines. The SEC-mandated prices used in determining our December 31, 2016 proved reserves and PV-10 value, as adjusted for quality and price differentials, were $38.67/Bbl for oil and condensate, $2.43/Mmbtu for natural gas and $13.62/Bbl for natural gas liquids, compared with SEC prices of $44.53/Bbl for oil and condensate, $2.63/Mmbtu for natural gas and $14.41/Bbl for natural gas liquids used in estimating proved reserves as of December 31, 2015. By contrast, the PV-10 value of our reserves based on strip prices at December 31, 2016 was approximately $268 million, compared to a PV-10 value of $272 million at the end of 2015.  Strip prices used in estimating the PV-10 of year-end 2016 reserves averaged $56.23/Bbl for oil and condensate, $3.08/Mmbtu for natural gas and $21.70 for natural gas liquids, compared to $50.93/Bbl for oil and condensate, $3.02/Mmbtu for natural gas and $11.88 for natural gas liquids at year-end 2015.

Our SEC proved developed reserves for the year ended December 31, 2016 were estimated at 129.4 Bcfe, compared to 157.2 Bcfe in the prior year. The decline in proved developed reserves can be attributed primarily to: approximately 26.0 Bcfe of production during the year; negative revisions of 3.2 Bcfe related to the reduction in the estimated economic life of certain properties due to the decrease in commodity prices; and sold reserves of 1.6 Bcfe in Colorado, partially offset by positive revisions of 2.9 Bcfe related to performance revisions and extensions.

Our SEC proved undeveloped reserves (“PUD”) for the year ended December 31, 2016 were 22.4 Bcfe, compared to 30 Bcfe at December 31, 2015.  The decrease in PUD reserves can be attributed primarily to negative revisions of 5.1 Bcfe related to the decrease in commodity prices and 2.5 Bcfe related to the sale of reserves in Colorado.

The above estimates do not include net proved reserves of approximately 32.6 Bcfe and 38.7 Bcfe attributable to our 37% equity ownership interest in Exaro Energy III LLC (“Exaro”) as of December 31, 2016 and 2015, respectively. The SEC PV-10 value of the proved reserves attributable to our 37% interest in Exaro was approximately $20 million at December 31, 2016, compared to the PV-10 value of $31 million as of December 31, 2015. 

Fourth Quarter Production

Production for the quarter ended December 31, 2016 was approximately 5.9 Bcfe, or 64.3 Mmcfed, within guidance for the quarter.  Current quarter production was less than the 8.0 Bcfe, or 87 Mmcfed, for the same period last year due to the reduced 2015 and 2016 capital expenditure programs and a 1.6 Mmcfed impact on the 2016 quarter from the shut-in of two wells in our conventional Liberty County area for workovers. Production for the current quarter was approximately 71% natural gas and 29% oil and natural gas liquids compared to the prior year quarter of 68% natural gas and 32% crude oil and natural gas liquids.  Natural gas production for the quarter is preliminarily estimated at approximately 45.8 Mmcfd compared to 59.3 Mmcfd for the prior year quarter, and crude oil and natural gas liquids production during the current period is preliminarily estimated at 1,380 and 1,700 barrels per day, respectively, compared to 2,100 and 2,475 barrels per day, respectively for the same quarter last year.  We currently estimate first quarter 2017 production to be between 57.4 and 62.4 Mmcfed, negatively impacted by an estimated 1.5 Mmcfed for the quarter because of the loss of compression at Eugene Island 11 for an estimated 24 days.

Liquidity

As of December 31, 2016, we had approximately $54.4 million of debt outstanding under our credit facility, a 13% decrease from the third quarter outstanding balance and a 53% decrease from the year-end 2015 outstanding balance.  Effective October 28, 2016, our $140 million borrowing base under our facility was reaffirmed through May 1, 2017.

Contango Oil & Gas Company is a Houston, Texas based, independent energy company engaged in the acquisition, exploration, development, exploitation and production of crude oil and natural gas offshore in the shallow waters of the Gulf of Mexico and in the onshore Texas Gulf Coast and Rocky Mountain regions of the United States. Additional information is available on the Company's website at http://contango.com .

This press release contains forward-looking statements regarding Contango that are intended to be covered by the safe harbor "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, based on Contango’s current expectations and includes statements regarding acquisitions and divestitures, estimates of future production, future results of operations, quality and nature of the asset base, the assumptions upon which estimates are based and other expectations, beliefs, plans, objectives, assumptions, strategies or statements about future events or performance (often, but not always, using words such as "expects", “projects”, "anticipates", "plans", "estimates", "potential", "possible", "probable", or "intends", or stating that certain actions, events or results "may", "will", "should", or "could" be taken, occur or be achieved). Statements concerning oil and gas reserves also may be deemed to be forward looking statements in that they reflect estimates based on certain assumptions that the resources involved can be economically exploited. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, which could cause actual results to differ materially from those, reflected in the statements. These risks include, but are not limited to: the risks of the oil and gas industry (for example, operational risks in exploring for, developing and producing crude oil and natural gas; risks and uncertainties involving geology of oil and gas deposits; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to future production, costs and expenses; potential delays or changes in plans with respect to exploration or development projects or capital expenditures; health, safety and environmental risks and risks related to weather such as hurricanes and other natural disasters); uncertainties as to the availability and cost of financing; fluctuations in oil and gas prices; risks associated with derivative positions; inability to realize expected value from acquisitions, inability of our management team to execute its plans to meet its goals, shortages of drilling equipment, oil field personnel and services, unavailability of gathering systems, pipelines and processing facilities and the possibility that government policies may change or governmental approvals may be delayed or withheld. Additional information on these and other factors which could affect Contango’s operations or financial results are included in Contango’s other reports on file with the Securities and Exchange Commission.  Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the projections in the forward-looking statements. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. Contango does not assume any obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Initial production rates are subject to decline over time and should not be regarded as reflective of sustained production levels.

Contact: Contango Oil & Gas Company E. Joseph Grady – 713-236-7400 Senior Vice President and Chief Financial Officer Sergio Castro – 713-236-7400 Vice President and Treasurer

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading